FIELD: biotechnology.
SUBSTANCE: invention is a nucleic acid encoding the human factor IX protein for the treatment of hemophilia B, where the said nucleic acid does not contain CpG dinucleotides. The invention also relates to a plasmid for the production of viral vectors for the treatment of hemophilia B and to a pharmaceutical composition for the treatment of hemophilia B.
EFFECT: invention makes it possible to effectively treat hemophilia B.
93 cl, 24 dwg, 4 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CODON-OPTIMIZED NUCLEIC ACID WHICH CODES BLOOD COAGULATION FACTOR IX PROTEIN, AND USE THEREOF | 2021 |
|
RU2831751C2 |
| VERSION OF AAV, COMPOSITIONS AND METHODS IN WHICH IT IS USED, AS WELL AS METHODS OF USING IT FOR TRANSFERRING GENES INTO CELLS, ORGANS AND TISSUES | 2014 |
|
RU2837753C2 |
| NON-DESTRUCTIVE GENE THERAPY FOR TREATING MMA | 2018 |
|
RU2820602C2 |
| METHOD OF PRODUCING MODIFIED CAPSID OF ADENO-ASSOCIATED VIRUS | 2021 |
|
RU2831732C1 |
| ISOLATED MODIFIED VP1 CAPSID PROTEIN OF ADENO-ASSOCIATED VIRUS OF SEROTYPE 5 (AAV5), CAPSID AND VECTOR BASED ON IT | 2019 |
|
RU2751592C2 |
| IX PADUA FACTOR ANTIBODIES | 2017 |
|
RU2770006C2 |
| GENE THERAPY OF HYPOPHOSPHATEMIC DISEASES ASSOCIATED WITH FIBROBLAST GROWTH FACTOR 23 | 2020 |
|
RU2815545C2 |
| ISOLATED MODIFIED VPI CAPSID PROTEIN OF ADENO-ASSOCIATED VIRUS OF SEROTYPE 9 (AAV9), CAPSID AND VECTOR BASED THEREON | 2021 |
|
RU2825667C2 |
| AAV VECTORS AIMED AT THE CENTRAL NERVOUS SYSTEM | 2015 |
|
RU2727015C2 |
| COMPOSITIONS AND METHODS FOR INCREASING OR ENHANCING TRANSDUCTION OF GENE THERAPY VECTORS AND FOR REMOVING OR REDUCING IMMUNOGLOBULINS | 2021 |
|
RU2841237C1 |
